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BRIEF DESCRIPTION OF BILIRUBIN METABOLISM 
In human plasma there are 4 main forms of circulating BL: unconjugated
bilirubin (UCB), also known as -bilirubin or indirect bilirubin (IB);
monoconjugate bilirubin (bilirubin-) or monoglucorunide (MGB) or conjugated
bilirubin (CB); diconjugated bilirubin (bilirubin ) or diglucorunide (DGB) or
direct bilirubin, also known as hepatic growth factor covalently bound to
albumin, irreversibly. Another BL fraction to consider is the free BL that is not
bound to albumin. BL is transported in plasma bound to Alb with a high affinity
bond to the Alb primary binding site. The free BL correlates better with BL
toxicity than any other fraction. The main source of BL is the heme group of
hemoglobin from the destruction of senescent erythrocytes, which contributes
around 80-85% of total production. The remaining 15 to 20% of BL production
results from the tournover of other liver hemeproteins such as myoglobin,
catalase and cytochrome. A small proportion (1-5%) results from the premature
destruction of premature erythrocytes in bone marrow or spleen. The heme
catabolism, resulting in BL production occurs within macrophages of the spleen,
bone marrow and in Kupffer cells. After the heme breakdown BL is released into
the plasma. In this mechanism, the ring of ferroprotoporfirina IX heme group, the
prosthetic group of proteins such as hemoglobin, myoglobin and cytochrome P-
450, suffers the catalytic action of heme oxygenase (HO-1). This enzyme
consumes three molecules of oxygen and requires a reducing agent, nicotinamide
adenine dinucletídeo phosphate (NADPH). The enzyme HO-1 acts at the central
bridge methionine, forming biliverdin (BLV) and is located in the plasma
membrane of the endoplasmic reticulum, nucleus and mitochondria. Its synthesis
is induced by stimuli associated with oxidative stress, including free oxygen and
bacterial lipopolysaccharide radicals by increasing the intracellular concentration
of hepatic heme induced by various drugs, natural compounds, cytokines and
growth factors. From the oxidation of heme it also results iron (Fe3 +), carbon
monoxide (CO) and BLV. The BLV is, in turn reduced to BL in a reaction that is
catalyzed by biliverdin reductase (BVR), dependent on NADPH. BL at this stage,
is called UCB and circulates in the blood bound to albumin.
Alb greatly enhances their solubility due to two binding sites for this molecule
and also prevents it is excreted into urine (15).
METHODS AND MATERIAL
Some studies point out that UCB may prevent cardiovascular disease
(CVD) and other chronic diseases. Clinical evidence indicates that
hyperbilirubinaemic individuals with GS, with mild hyperbilirubinemia,
are at reduced risk of developing cardiovascular and chronic kidney
disease. There are currently several studies that have established an
association between low BL and the presence and severity of various
cardiovascular diseases and the respective causes or co-morbidities such
as, type 2 diabetes, metabolic syndrome, hypertension, chronic kidney
disease and albuminuria. It was observed the same association, as
described above, with other disease conditions which physiopathology is
related to oxidative stress, such as rheumatoid arthritis, multiple
sclerosis, cancer and overall mortality.
RESULTS
CONCLUSION
In a hyperbilirubinemic condition, were it is important to lower serum bilirubin
levels, the best approach would include the increasing UGT1A1 expression and
this can be achieved with foods from the botanical families Cruciferae (e.g.,
broccoli), Rutaceae (citrus), Liliaceae (e.g., onions), and Leguminosae
(legumes). Regulation of UGTs by phytochemicals has been investigated with a
focus on cancer prevention numerous inhibitors from plant origin (epicatechin
gallate, epigallocatechin gallate, octyl gallate, propyl gallate, quercetin, tannic
acid, benzoin gum, capsaicin, dihydrocapsaicin, eugenol, gallocatechin gallate,
geraniol, menthol, menthyl acetate, naringenin, allspice berry oil, N-
vanillylnonanamide, clovebud oil, peppermint oil, silibinin, and silymarin). The
strategy to rise SBL, inhibiting UGT1A1 activity appears unreasonable because
UGT1A1 also glucuronides, estrogens and several dietary carcinogens.
Several studies show that low serum bilirubin concentrations are associated
with an increased risk of chronic diseases, whereas slightly elevated serum
bilirubin levels seems to provide protection. The enzymes HO-1 and BLV will
also have an important role in the development of therapeutic strategies based
on dietary compounds however for these two enzymes there was considerable
less information about their inducers and inhibitors.
Fig. (1). Bilirubin hepatic uptake, conjugation and glucoronid transporters. SER: smooth endoplasmic reticulum; UCB:
unconjugated bilirubin; Alb: albumin; MGB e DGB: mono and diglucuronid; Y: ligandin; UGT1A1: uridine 5'-diphospho-
glucuronosyltransferase 1A1 (UDP-glucuronosyltransferase, UGT); UDPGlcUA: glucuronic acid residue; OATP1B1/3: organic
anion transporter, 1B1 and 1B3; ABCC3: ATP-Binding Cassette transporter, (Sub-Family C, CFTR/MRP, Member 3); MRP2:
Multidrug Resistance-associated Protein 2; ABCC2: ATP-Binding Cassette transporter (sub-family G member 2). The image also
shows the location of UGT1A1 in the membrane of smooth endoplasmic reticulum membrane (SER); transport of unconjugated
bilirubin (UCB) into hepatocyte at the sinusoidal surface by the action of the organic anion basolateral transporters OATP1B1/3
(organic anion transporter, 1B1 and 1B3); ligandin assembles and transport UCB to the SER; conjugation of UCB by UGT1A1
results in bilirubin glucuronides (MGB, DGB); glucuronides are water soluble and are transported to the exterior of the hepatocyte,
at the apical canalicular surface, by the MRP2 (Multidrug Resistance-Associated Protein 2) and ABCC2 (ATP-Binding Cassette
transporter - sub-family G member 2), and possibly by the ligandin (initially named Y protein) a glutathione-S-transferases (17),
which despite being in much smaller quantity, can pass through the protein ABCC3 a ATP-Binding Cassette transporter, (Sub-Family
C, CFTR/MRP, Member 3) and be again captured by OATP transporters.
DRUG INTERACTION WITH BILIRUBIN METABOLISM
Many exogenous substances, xenobiotics and drugs are substrates of UGT1A1
enzyme. Genetic variations that alter the expression of UGT1A1 may be a danger
as they would increase toxicity for patients. The variant most studied in this
interaction corresponds to the polymorphism UGT1A1 * 28, at the UGT1A1
promoter responsible for the GS, characterized by hiperbilirubinemia. Examples
of UGT1A1 substrates are irinotecan (SN-38), acetaminophen (paracetamol) and
simvastatin (8).
Dietary compounds or dietary sources 
intake
Type of study Effect on bilirubin levels
Summary
Record of food intake from four
botanical groups: Cruciferae,
Rutaceae, Liliaceae and Leguminosae.
Observational
Decreased SBL. Only homozygotes 7/7 showed 
decreased bilirubin concentrations after consuming 
cruciferous vegetables but not with the intake of other 
investigated botanical groups. 
Cruciferous, citrus and soy 
(doses adjustusd for body weight)
Clinical Decreased SBL. The intake of cruciferous vegetables, 
soy foods and citrus fruit seems was associated to a 
decrease on SBL but only in women that are 
homozygous 7/7.
Record of food intake Citrus fruit, 
cruciferous and soy
Observational
Decreased SBL. Women homozygous 7/7 that consume 
citrus fruit may exhibit a higher activity of this gene 
than those who do not include it on their diet.
Cruciferous, citrus and soy 
(Different quantities of Cruciferous 
supplementation)
Clinical Decreased SBL within all of  three group of vegetable 
and it was observed in the three genotypes. Results 
suggest a dose-response.
Soy In vivo Decreased
Resveratrol
(Resveratrol doses)
Clinical Decreased SBL. UGT1A1 activities were minimally 
affected by the intervention. is more pronounced in 
individuals with low baseline enzyme activity.
Dandelion In vivo Decreased 
Rooibos In vivo Decreased 
Honeybush tea In vivo Decreased
Rosemery In vivo Decreased
Ellagic acid (present in berryes, 
pomegranate, grapes, walnuts, and 
blackcurrants)
In vivo Decreased
Ferulic acid In vivo Decreased
Curcumin In vivo Decreased
Astaxanthin In vivo Decreased
Green tea In vitro Increased 
Green tea In vitro Increased
Quercetin In vitro Increased
Rutin In vitro Increased
Naringenin In vitro Increased
Allspice In vitro Increased
Peppermint oil In vitro Increased
Cacao In vitro Increased
Table 2. Sources or dietary compounds that can modulate serum bilirubin levels by interfering 
with UGT1A1 activity.
Bilirubin (BL) is a yellow-orange pigment resulting from the catabolism of
hemeproteins. This tetrapirrolic metabolite belongs to one of the most
conserved superfamily of molecules in living, organisms. The BL has been
subject of study for more than three centuries. In clinical diagnosis, BL is a
marker of liver function and used to monitoring hematological diseases. The
enzyme that catalyzes BL conjugation is the uridine diphosphate glucuronyl
transferase 1A1 (UGT1A1). Unconjugated BL (UCB) is lipid soluble
molecule but after conjugation (with one or two molecules of glucuronic
acid) becomes water soluble (conjugated bilirubin: CB), allowing its
excretion via the bile canaliculi. The most prevalent metabolic disorder in
the Caucasian population is Gilbert's syndrome (GS). It´s a benign
condition, characterized by moderate hyperbilirubinemia in the absence of
hemolysis or liver dysfunction. The common variant associated with this
syndrome is the TA duplication at position c.-41_-40dupTA (variant
UGT1A1*28 or A(TA)7TAA allele) located in the promoter region of the
UGT1A1 gene. The presence of hyperbilirubinemia, associated with GS, can
lead to the worsening of clinical symptoms of individuals with chronic
hemolytic diseases.
At high concentrations, as described in children with Crigler-Najjar
syndrome type I (SCN-I) or type II (SCN-II), BL can be extremely toxic.
However, in the past 20 years, the possible antioxidant, anti-inflammatory
and anti-carcinogenic properties, observed in the presence of mild elevated
SBL, have been motivated researchers to conduct numerous epidemiological
and experimental studies to clarify the mechanisms involved in its potential
protective effect.
Observation of in vitro and in vivo studies suggest that certain dietary
compounds may increase or decrease BL levels. It is well known that drugs
and other substances that can compete with BL for glucuronidation also
contribute to the raising of SBL. Some herbal extracts can even exert
inhibitory effects of UGT1A1 activity and thereby increase BL levels. On
the other hand, there are dietary components that increase enzymatic activity
of UGT1A1 , such as citrus fruit and some constituents of such Cruciferous
vegetables (eg. cabbage and broccoli) by increasing the expression of
UGT1A1 gene. In animal models it was demonstrated that soy protein and
soy isoflavones enhance hepatic UGT activity.
INTRODUCTION
After hepatic uptake and metabolism, BL may remain in the liver cells (storage)
connected to cytoplasmic proteins. It can also move to the smooth endoplasmic
reticulum of the hepatocyte and undergo conjugation with one or two residues
of glucuronic acid ( UDPGlcUA) by the catalytic action of UGT1A1 forming
monoglucorunídeo (MGB) or diglucorunídeo (DGB ), named as conjugated
bilirubin (CB). In the gut this CB undergoes oxidation by the action of intestinal
enzymes and bacterial flora and urobilinogen is formed as other pigments. The
Urobilinogen may again be captured to the liver (enterohepatic circulation) and
may be conjugated.
The liver plays a central role in the metabolism of BL. It is responsible for their
capture, storage, conjugation and excretion. The BNC circulates in plasma in a
complex bound to Alb ( BL- Alb ) entering the hepatocyte by its surface
sinusoidal (figure 1).
An extensive variety of fruits and vegetables offer a range of nutrients and
different bioactive compounds including phytochemicals, vitamins, minerals,
and fibers. Many dietary compounds, present in fruits, vegetables and spices
have been isolated and evaluated for their therapeutic potential. Evidence
suggests that the health benefits of fruits and vegetables are attributed to the
interactions of the phytochemicals present in whole foods by modulating
several metabolic pathways. The impression that these compounds have health
promoting effects emerged because their consumption was related to a reduced
incidence of cancer, cardiovascular, neurological, respiratory, and age related
diseases (21).
